MAPT and Alzheimer disease: Notably, administration of insulin and IGF‐1 could improve metabolic integrity in AD patients [42, 56], as well as improve cognitive function by alleviating synaptic loss, inhibiting tau phosphorylation and brain atrophy in AD patients [10].